Phibro Animal Health (NASDAQ:PAHC) CEO Sells $361,644.80 in Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 7,040 shares of the firm’s stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $51.37, for a total transaction of $361,644.80. Following the transaction, the chief executive officer directly owned 15,560 shares of the company’s stock, valued at $799,317.20. The trade was a 31.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Jack Bendheim also recently made the following trade(s):

• On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $53.73, for a total value of $378,259.20.
• On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.42, for a total value of $361,996.80.
• On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.40, for a total value of $361,856.00.
• On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.96, for a total value of $365,798.40.
• On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.62, for a total value of $732,178.08.
• On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.81, for a total transaction of $3,005,705.34.
• On Thursday, February 5th, Jack Bendheim sold 110,842 shares of Phibro Animal Health stock. The stock was sold at an average price of $48.38, for a total transaction of $5,362,535.96.
• On Wednesday, February 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.15, for a total value of $144,848.00.
• On Tuesday, February 3rd, Jack Bendheim sold 9,660 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.47, for a total value of $400,600.20.
• On Friday, January 30th, Jack Bendheim sold 6,693 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total value of $268,322.37.

Phibro Animal Health Stock Up 3.0%

NASDAQ:PAHC traded up $1.60 during mid-day trading on Thursday, reaching $54.70. The company’s stock had a trading volume of 307,502 shares, compared to its average volume of 260,132. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14. Phibro Animal Health Corporation has a 1 year low of $16.16 and a 1 year high of $56.30. The stock has a fifty day moving average of $43.41 and a 200-day moving average of $40.66. The firm has a market capitalization of $2.22 billion, a PE ratio of 24.31, a price-to-earnings-growth ratio of 0.79 and a beta of 0.80.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.69 by $0.18. The business had revenue of $373.91 million during the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Equities research analysts forecast that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th will be issued a $0.12 dividend. The ex-dividend date is Wednesday, March 4th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.9%. Phibro Animal Health’s dividend payout ratio (DPR) is currently 21.33%.

Institutional Investors Weigh In On Phibro Animal Health

Institutional investors and hedge funds have recently made changes to their positions in the stock. Caitlin John LLC purchased a new stake in shares of Phibro Animal Health during the fourth quarter valued at $266,000. Mackenzie Financial Corp lifted its position in Phibro Animal Health by 7.1% during the 4th quarter. Mackenzie Financial Corp now owns 50,619 shares of the company’s stock worth $1,895,000 after acquiring an additional 3,355 shares during the period. XTX Topco Ltd grew its stake in Phibro Animal Health by 125.4% during the 4th quarter. XTX Topco Ltd now owns 16,233 shares of the company’s stock valued at $606,000 after purchasing an additional 9,032 shares during the last quarter. Zacks Investment Management increased its holdings in shares of Phibro Animal Health by 13.2% in the fourth quarter. Zacks Investment Management now owns 91,391 shares of the company’s stock valued at $3,414,000 after purchasing an additional 10,642 shares during the period. Finally, VARCOV Co. purchased a new position in shares of Phibro Animal Health in the fourth quarter worth about $672,000. 99.34% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PAHC has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Morgan Stanley set a $49.00 price target on shares of Phibro Animal Health in a report on Friday, February 6th. JPMorgan Chase & Co. increased their target price on shares of Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Finally, Zacks Research downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 9th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $37.50.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.